
Summary:
In this podcast from the 2023 DPHARM meeting, senior industry leaders discussed the pandemic's impact on the abrupt transition to DCTs, and where that leaves us in the current day when it comes to determining the value proposition of patient-enabled tech. They focused on the operating models required for patient-enabled trial technologies, the realities that can propel or stifle innovation, AI's potential for streamline clinical operations, and more.
For more information about DPHARM, visit DPHARMconference.com.
Speakers ModeratorsRelated Podcasts
View All
Tufts Center for Study of Drug Development on Evolving Clinical Trial Partnerships

Boehringer Ingelheim on Collaborations in Clinical Development for Launch Readiness

How Roche Maximizes the Impact of Patient Insights in Early Development for a Blueprint to De-Risk Molecule Development
